E. Nievergall

发表

PTP1B regulates Eph receptor function and trafficking

E. Nievergall, P. W. Janes, Carolin Stegmayer, 2010, The Journal of cell biology.

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL

E. Nievergall, T. Révész, S. Heatley, 2016, Bone Marrow Transplantation.

Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

E. Nievergall, Angel F. Lopez, H. Ramshaw, 2014, Blood.

depletes CML progenitor and stem cells with CSL362 effectively α Monoclonal antibody targeting of IL-3 receptor

E. Nievergall, Angel F. Lopez, H. Ramshaw, 2014 .

Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data

A. Zannettino, E. Nievergall, S. Paisitkriangkrai, 2018, Molecular Genetics and Genomics.

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment

D. J. Moulton, E. Nievergall, C. Mullighan, 2014, Leukemia.

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

E. Nievergall, D. Ross, D. White, 2013, Haematologica.

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

E. Nievergall, D. White, T. Hughes, 2014, Leukemia.

Adam Meets Eph: An ADAM Substrate Recognition Module Acts as a Molecular Switch for Ephrin Cleavage In trans

C. Blobel, E. Nievergall, P. W. Janes, 2005, Cell.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

H. Goldschmidt, E. Nievergall, T. Holderried, 2022, The Lancet. Haematology.

Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells.

E. Nievergall, M. Lackmann, A. Boyd, 2008, Blood.

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

M. Caligiuri, M. Konantz, C. Lengerke, 2019, Nature.

Concepts and consequences of Eph receptor clustering.

E. Nievergall, P. W. Janes, M. Lackmann, 2012, Seminars in cell & developmental biology.

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

E. Nievergall, C. Mullighan, T. Révész, 2017, Haematologica.

Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors

T. Pawson, C. Jørgensen, E. Nievergall, 2011, The Journal of cell biology.

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

E. Nievergall, J. Reynolds, W. Erber, 2016, Leukemia.

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

H. Goldschmidt, E. Nievergall, T. Holderried, 2021, Blood.

Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data

A. Zannettino, E. Nievergall, S. Paisitkriangkrai, 2018, Molecular Genetics and Genomics.

Eph-dependent cell-cell adhesion and segregation in development and cancer

E. Nievergall, P. W. Janes, M. Lackmann, 2011, Cellular and Molecular Life Sciences.

PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling

E. Nievergall, P. W. Janes, M. Lackmann, 2016, Journal of Cell Science.